Essen Biotech
4 clinical trials · 4 recruiting · OTHER
Trials by Essen Biotech
RECRUITINGPhase 1 / Phase 2NCT07410676
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting...
Sponsor: Essen BiotechEnrolling: 831 location
CancerSarcomaLeukaemia+12
RECRUITINGPhase 1 / Phase 2NCT06420063
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD33 or CD123 or both...
Sponsor: Essen BiotechEnrolling: 851 location
AMLAcute Myeloid LeukemiaAML, Adult Recurrent+1
RECRUITINGPhase 1 / Phase 2NCT06350110
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002...
Sponsor: Essen BiotechEnrolling: 751 location
Systemic Lupus ErythematosusLupus NephritisAutoimmune Diseases+6
RECRUITINGPhase 1 / Phase 2NCT06428188
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or CD19 or both...
Sponsor: Essen BiotechEnrolling: 601 location
Autoimmune DiseasesSystemic Lupus ErythematosusSystemic Lupus Erythematosus Acute+1